Welcome to our dedicated page for Theravance Bioph SEC filings (Ticker: TBPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Theravance Biopharma, Inc. filings document operating results, material events, governance matters, and portfolio disclosures for a Cayman Islands biopharmaceutical issuer. Form 8-K reports furnish quarterly and annual financial updates, YUPELRI collaboration revenue, business updates, Regulation FD materials, and financial-condition disclosures tied to the company’s therapeutics business.
The filing record also covers product and intellectual-property matters, including a Hatch-Waxman settlement resolving ANDA patent litigation involving YUPELRI® (revefenacin) inhalation solution. Other disclosures address the ampreloxetine Phase 3 CYPRESS outcome, costs associated with organizational restructuring and program wind-down activities, annual general meeting voting matters, director elections, and proxy governance.
Theravance Biopharma, Inc. reported the results of its 2026 Annual General Meeting of Shareholders held on June 12, 2026. Shareholders holding 47,059,878 ordinary shares, or 91.4% of shares entitled to vote, were present, providing a quorum to conduct business.
All director nominees, including Laurie Smaldone Alsup, Susannah Gray, Dean J. Mitchell, Donal O’Connor, Deepika R. Pakianathan, and Rick E. Winningham, were elected to serve until the 2027 annual meeting. Shareholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
In addition, shareholders approved a non-binding advisory resolution on the compensation of the company’s named executive officers, indicating overall support for the current executive pay program.
Theravance Biopharma, Inc. chief executive officer Rick E. Winningham reported a routine tax-related share withholding. On May 20, 2026, 20,038 Ordinary Shares were withheld at $16.55 per share to satisfy tax obligations from vesting restricted stock units, in a transaction with the company rather than in the open market.
After this withholding, he directly held 1,631,056 Ordinary Shares. He also reported indirect holdings of 92,567 Ordinary Shares held by a trust and 23,400 Ordinary Shares held as custodian.
Theravance Biopharma, Inc. reported that SVP & Chief Financial Officer Aziz Sawaf had 8,670 Ordinary Shares withheld at a price of $16.55 per share to cover tax obligations from vesting restricted stock units. This was a share withholding with the company, not an open market trade. After this routine tax-withholding transaction, Sawaf directly holds 344,953 Ordinary Shares.
Theravance Biopharma SVP Aine Miller reported a routine tax-withholding transaction related to equity compensation. On the vesting of previously granted restricted stock units, 6,827 Ordinary Shares were withheld at $16.55 per share to satisfy tax obligations in a transaction with the issuer, not the open market. After this withholding, Miller directly holds 177,334 Ordinary Shares.
Theravance Biopharma SVP Brett A. Grimaud had 8,829 Ordinary Shares withheld at $16.55 per share to cover taxes on vested restricted stock units. The shares were withheld by the company, not sold in the open market. After this tax-withholding transaction, he directly holds 363,120 Ordinary Shares.
Theravance Biopharma, Inc. senior vice president Rhonda Farnum reported a routine tax-withholding share disposition tied to equity compensation. On the vesting of previously granted restricted stock units, 5,678 Ordinary Shares were withheld at $16.55 per share to satisfy tax obligations. The shares were withheld by the company and did not involve any open-market transaction. After this non-market disposition, Farnum directly holds 245,771 Ordinary Shares, indicating she retains a substantial equity stake following the tax payment event.
Theravance Biopharma’s first-quarter 2026 results show a sharp strategic pivot after a key trial setback. Revenue from the Viatris collaboration grew to $17.7 million, driven by YUPELRI, while net loss narrowed to $4.9 million compared with $13.6 million a year earlier.
YUPELRI net sales recorded by Viatris reached $62.4 million, up 7%, implying $21.9 million for Theravance’s 35% share. Cash, cash equivalents and marketable securities totaled about $394.7 million with no long-term debt, boosted by TRELEGY and YUPELRI milestones.
After the ampreloxetine Phase 3 CYPRESS study failed its primary endpoint, the company is winding down the program, cutting about 50% of its 90 employees and implementing a restructuring expected to reduce operating expenses by roughly 60% versus 2025 and deliver about $70 million in annualized savings from the third quarter of 2026. A Board Strategic Review Committee is actively evaluating alternatives, including a possible sale of the company, while Theravance concentrates on its commercial YUPELRI franchise and remaining TRELEGY milestone upside.
Theravance Biopharma reported improved first-quarter 2026 results and detailed a major restructuring to become a cash-generative, YUPELRI-focused company. Revenue rose to $17.7 million from $15.4 million, and the GAAP net loss narrowed to $4.9 million from $13.6 million. Non-GAAP results turned to a $0.6 million profit versus an $8.6 million loss a year earlier, helped by YUPELRI net sales of $62.4 million recorded by Viatris, of which Theravance’s implied 35% share was $21.9 million.
The company plans an organizational restructuring that winds down R&D, cuts G&A about 50% and is expected to reduce operating expenses by roughly 60% versus 2025 actuals of $111.1 million. Management targets about $70 million of full run-rate cost savings and approximately $60–70 million of annualized cash flow starting in the third quarter of 2026, excluding any potential $100 million TRELEGY milestone. Around 50% of the workforce will be affected, with $5–7 million of one-time cash severance costs. A Board Strategic Review Committee continues to evaluate alternatives, including a potential sale of the company.
Theravance Biopharma, Inc. is asking shareholders to vote at its 2026 Annual General Meeting on June 12, 2026 in Dublin, Ireland. Shareholders will elect six directors to one‑year terms, ratify Ernst & Young LLP as independent auditor for 2026, and approve a non‑binding advisory vote on executive pay.
The board is being reduced from nine to six members and fully declassified, so all directors stand for annual election. The company highlights pay-for-performance features in 2025 executive compensation and details strong governance practices, independent board leadership, and active board committees overseeing strategy, risk, and capital allocation.
Theravance Biopharma CEO Rick E. Winningham received an equity grant of 75,000 Ordinary Shares at no cost. The award was recorded as a grant or other acquisition on Ordinary Shares.
Following this grant, he directly holds 1,651,094 Ordinary Shares and also reports indirect holdings of 23,400 shares as custodian and 92,567 shares held by a trust.